Bristol-Myers Squibb ’s small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland was sold in June to SK Biotek, a wholly-owned subsidiary of South Korean SK Holdings. The deal is expected to close by the fourth quarter 2017. According to the companies, SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site. SK Biotek will operate the plant as a stand-alone contract development manufacturing organization (CDMO), and it intends to add marketing, research and development (R&D) talent, and invest in upgrades to bring additional capacity to the site

LEAVE A REPLY

Please enter your comment!
Please enter your name here